Core Viewpoint - The company has made significant progress in its operations, including the transfer of equity stakes, approval for new facilities, and advancements in clinical trials and smart factory construction. Group 1: Financial and Shareholder Information - The company plans to distribute a cash dividend of 1.50 yuan per 10 shares to all shareholders, based on a total of 504,248,738 shares [1] - There has been no change in the controlling shareholder or actual controller during the reporting period [1] Group 2: Major Corporate Actions - The company has approved the public transfer of 80% equity in Jiangxi Boya Xinha Pharmaceutical Co., Ltd., with a revised listing price of 158.1655 million yuan [3][4] - The company received approval to establish a single plasma collection station in Dalat Qi, Inner Mongolia [5] - The company obtained clinical trial approval for subcutaneous immunoglobulin and a supplementary drug application for intravenous immunoglobulin [6] Group 3: Operational Developments - The construction of the blood product smart factory is progressing well, with the main structure completed and various installations underway [6] - The company aims to set high standards for the smart factory project, positioning it as a benchmark in the biopharmaceutical industry [6] Group 4: Shareholder Actions - The controlling shareholder, China Resources Pharmaceutical Holdings Co., Ltd., has completed a share buyback plan, acquiring a total of 6,050,900 shares, representing 1.2% of the total share capital [7][8]